SEATTLE, May 25, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global urea cycle disorders treatment market is estimated to be valued at US$ 1,188.9 million in 2020 and is expected to exhibit a CAGR of 3.5 % during the forecast period (2020-2027).
Key Trends and Analysis of the Global Urea Cycle Disorders Treatment Market:
The rising prevalence of urea cycle disorders is expected to increase the demand for treatment options for urea cycle disorders (UCD), which is expected to drive the growth of global urea cycle disorders treatment market during the forecast period. According to the Urea Cycle Disorders Consortium (UCDC), a part of the Rare Diseases Clinical Research Network (RDCRN), combined prevalence of urea cycle disorders is around 1 in 30,000 people in the U.S in 2017
Among regions, North America is expected to hold dominant position in the global urea cycle disorders treatment market during the forecast period, owing to key companies focusing on product launches for the treatment of Urea cycle disorders. For instance, in January 2021, Recordati Rare Diseases Inc. received the U.S. Food and Drug Administration (FDA) approval for CARBAGLU for the treatment of acute hyperammonemia.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4441
Key Market Takeaways:
The global urea cycle disorders treatment market is expected to exhibit a CAGR of 3.5 % during the forecast period, owing to increasing number of pipeline products. For instance, in April, 2019, Aeglea Biotherapeutics, a late clinical-stage biotechnology company, initiated phase 3 clinical trial study for the efficacy and safety of Pegzilarginase in children and adults with Arginase 1 deficiency. The study is estimated to be completed in June 2023.
Competitive Landscape:
Key players operating in the global urea cycle disorders treatment market include Bausch Health Companies, Inc., Recordati Rare Diseases Inc., Lucane Pharma SA, Acer Therapeutics, Ultragenyx Pharmaceutical Inc., Aeglea BioTherapeutics, Arcturus Therapeutics Holdings Inc., Orpharma Pty Ltd., Selecta Biosciences, Inc., Abbott Laboratories, NESTLÉ S.A., DANONE S.A., and Mead Johnson & Company, LLC.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4441
Market Segmentation:
- Global Urea Cycle Disorders Treatment Market, By Treatment Type:
- Amino Acid Supplements
- Sodium Phenylbutyrate
- Glycerol Phenylbutyrate
- Sodium Benzoate
- Others (Low Protein Diet, Carglumic acid, etc.)
- Global Urea Cycle Disorders Treatment Market, By Enzyme Deficiency Type :
- OTC – Ornithine Transcarbamylase
- AS – Argininosuccinate Synthetase (citrullinemia)
- AG – Arginase
- AL – Argininosuccinate Lyase
- CPS1 – Carbamoyl Phosphate Synthase
- NAGS – N-acetylglutamate Synthase
- Global Urea Cycle Disorders Treatment Market, By Route of Administration :
- Oral
- Injectable
- Global Urea Cycle Disorders Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Urea Cycle Disorders Treatment Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Europe
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country:
- Middle East
- By Country/Region:
- GCC
- Israel
- Rest of Middle East
- By Country/Region:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- North America
Related Market Intelligence Reports:
Cholangiocarcinoma Market, By Treatment Type (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine, and 5 fluorouracil (5-FU)), Targeted Therapy (Pemigatinib, Infigratinib (Phase 3), Ivosidenib (Phase 3)), Immunotherapy, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 – 2028
Read more: https://www.coherentmarketinsights.com/market-insight/cholangiocarcinoma-market-4435
Agitation in Delirium Management Market, by Drug (First-generation Antipsychotics, Second-generation Antipsychotics, Benzodiazepines, and Others), by Route of Administration (Oral, Intramuscular, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
Read more: https://www.coherentmarketinsights.com/market-insight/agitation-in-delirium-management-market-4430
Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Drug Type (Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 – 2028
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.